Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine in Mechanically Ventilated Patients
Mechanical Ventilation, Complication, Delirium
About this trial
This is an interventional treatment trial for Mechanical Ventilation focused on measuring sedation, Midazolam, Propofol, Dexmedetomidine
Eligibility Criteria
Inclusion Criteria:
- Intubated patients;
- Age≥18 years old;
- Anticipated Ventilation and sedation duration of at least 72 hours.
Exclusion Criteria:
- Allergy to the study drug;
- suspected pregnancy;
- gross obesity;
- Extremely unstable of circulatory system, such as systolic blood pressure less than 90 mm Hg despite plasma volume expansion and continuous infusions of vasopressors before the start of study drug infusion;
- Uncontrolled abnormal hypertension, such as systolic blood pressure more than 180 mmHg or diastolic more than105 mmHg;
- Heart rate less than 50 bpm;
- Second or third degree heart block;
- moribund state;
- history of alcoholism or intake of anti-anxiety drugs or hypnotics;
- chronic renal failure;
- coma by cranial trauma or neurosurgery or unknown etiology or epileptic state;
- History of neuromuscular disease;
- unwillingness to provide informed consent by patients or their authorized surrogates following ICU admission.
Sites / Locations
- Department of Critical care medicine of West China Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
midazolam
midazolam/propofol
midazolam/dexmedetomidine
Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation.
Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.
Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation. After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation.